EU: Stardust (STD)
The main goal of the STARDUST project is to realize a novel wireless implantable and independent micro-scale device (200x200x200 μm3) enabling in-vivo electrophysiology, optogenetics and ultra-localized drug delivery in freely moving animals. The device will be used to target specific neural circuits of the brain and test a new therapeutic approach for Parkinson’s Disease.
The methods used in this project are based on cutting-edge miniaturized technology combining integrated chips, microelectromechanical systems (MEMS), local drug delivery, integrated electrodes and micro-scale light emitting diodes (μLEDs), enabling an implantable ultrasonically-powered miniaturized device for in-vivo optogenetics, local drug delivery and electrophysiological monitoring – all in one single device.
The main novelty of the STARDUST project is the convergence of multiple, interdisciplinary fields including optogenetics, triggered drug-delivery, miniaturized ultrasonic energy harvesting, material science and nanoelectronics.
The main ambition of the project is to develop a new technology platform to be used for future implantable in-vivo optogenetic devices for monitoring and treating diseases, with an optional local drug delivery add-on beyond 2025.
Beteiligte externe Organisationen
Mittelgeber
Europäische Union (EU) - HU als Beteiligte
Laufzeit
Projektstart: 10/2017
Projektende: 06/2022
